BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 12386337)

  • 1. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.
    Ma J; Wollmann R; Lindquist S
    Science; 2002 Nov; 298(5599):1781-5. PubMed ID: 12386337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol.
    Ma J; Lindquist S
    Science; 2002 Nov; 298(5599):1785-8. PubMed ID: 12386336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosolic prion protein toxicity is independent of cellular prion protein expression and prion propagation.
    Norstrom EM; Ciaccio MF; Rassbach B; Wollmann R; Mastrianni JA
    J Virol; 2007 Mar; 81(6):2831-7. PubMed ID: 17182694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations.
    Fioriti L; Dossena S; Stewart LR; Stewart RS; Harris DA; Forloni G; Chiesa R
    J Biol Chem; 2005 Mar; 280(12):11320-8. PubMed ID: 15632159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of neurotoxicity of pathological prion protein.
    Castilla J; Hetz C; Soto C
    Curr Mol Med; 2004 Jun; 4(4):397-403. PubMed ID: 15354870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
    Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
    Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.
    Ma J; Lindquist S
    Proc Natl Acad Sci U S A; 2001 Dec; 98(26):14955-60. PubMed ID: 11742063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion proteins meet protein quality control.
    Dimcheff DE; Portis JL; Caughey B
    Trends Cell Biol; 2003 Jul; 13(7):337-40. PubMed ID: 12837603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggresome formation by mutant prion proteins: the unfolding role of proteasomes in familial prion disorders.
    Mishra RS; Bose S; Gu Y; Li R; Singh N
    J Alzheimers Dis; 2003 Feb; 5(1):15-23. PubMed ID: 12590162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion diseases: what is the neurotoxic molecule?
    Chiesa R; Harris DA
    Neurobiol Dis; 2001 Oct; 8(5):743-63. PubMed ID: 11592845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A transmembrane form of the prion protein in neurodegenerative disease.
    Hegde RS; Mastrianni JA; Scott MR; DeFea KA; Tremblay P; Torchia M; DeArmond SJ; Prusiner SB; Lingappa VR
    Science; 1998 Feb; 279(5352):827-34. PubMed ID: 9452375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death.
    Cronier S; Laude H; Peyrin JM
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12271-6. PubMed ID: 15302929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmissible and genetic prion diseases share a common pathway of neurodegeneration.
    Hegde RS; Tremblay P; Groth D; DeArmond SJ; Prusiner SB; Lingappa VR
    Nature; 1999 Dec; 402(6763):822-6. PubMed ID: 10617204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calpain and other cytosolic proteases can contribute to the degradation of retro-translocated prion protein in the cytosol.
    Wang X; Wang F; Sy MS; Ma J
    J Biol Chem; 2005 Jan; 280(1):317-25. PubMed ID: 15525638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein.
    Yedidia Y; Horonchik L; Tzaban S; Yanai A; Taraboulos A
    EMBO J; 2001 Oct; 20(19):5383-91. PubMed ID: 11574470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons.
    Roucou X; Guo Q; Zhang Y; Goodyer CG; LeBlanc AC
    J Biol Chem; 2003 Oct; 278(42):40877-81. PubMed ID: 12917444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
    Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
    J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.
    Kristiansen M; Messenger MJ; Klöhn PC; Brandner S; Wadsworth JD; Collinge J; Tabrizi SJ
    J Biol Chem; 2005 Nov; 280(46):38851-61. PubMed ID: 16157591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A transgenic model of a familial prion disease.
    Harris DA; Chiesa R; Drisaldi B; Quaglio E; Migheli A; Piccardo P; Ghetti B
    Arch Virol Suppl; 2000; (16):103-12. PubMed ID: 11214912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
    Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
    Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.